Insufficient Evidence of Aducanumab Efficacy, ICER Draft Report Finds

Insufficient Evidence of Aducanumab Efficacy, ICER Draft Report Finds

293881

Insufficient Evidence of Aducanumab Efficacy, ICER Draft Report Finds

A draft report from the Institute for Clinical and Economic Review, known as ICER, found that there is insufficient evidence to determine whether the investigational therapy aducanumab will provide health benefits to people with Alzheimer’s disease. ICER is an independent non-profit research institute that works to assess the effectiveness and value of medicines and other medical services. Notably, the institute’s Draft Evidence Report represents the midpoint of ICER’s assessment of the evidence on aducanumab —…

You must be logged in to read/download the full post.